Cancer and Blood Clots: What You Need to Know About Thrombosis and Bleeding
"Understanding the delicate balance between thrombosis and bleeding in cancer patients can improve overall health and treatment outcomes."
For over a century, medical professionals have recognized the connection between cancer and hypercoagulability – an increased tendency to form blood clots. Armand Trousseau first described the association in the 19th century. Cancer patients often experience an imbalance, predisposing them to both thrombosis (clotting) and bleeding.
While the presence of malignant cells contributes to coagulation, it’s now understood that the process is far more complex. The type of cancer, its stage, and treatments all play a role, making personalized understanding critical. Specific genetic alterations, especially in hematological malignancies, can further heighten thrombotic risks.
Navigating these complexities requires a comprehensive approach. This article reviews current insights into thrombosis and bleeding in cancer patients, offering practical information to help understand, manage, and mitigate these risks.
Bleeding Is an Understudied Risk
Cancer care can be complicated by both thrombosis and bleeding, but bleeding has received less attention than venous thromboembolism (VTE). A prospective cohort study described in a 2024 report set out to examine bleeding incidence, risk factors, and prognosis among patients with cancer starting systemic anticancer therapy; its abstract notes that data on bleeding events remain sparse. Separately, a study using the Epic Cosmos database investigated clinically relevant bleeding in people with cancer, underscoring efforts to address this knowledge gap. The available source details do not provide numerical incidence estimates.
Balancing Clot Prevention and Bleeding Risk
Cancer-associated thrombosis (CAT) management must balance the risk of recurrent thrombosis against bleeding, while accounting for anticancer drug interactions and situations such as thrombocytopenia, brain metastases, gastrointestinal malignancies, and catheter-related events. A 2025 review describes malignancy-related hypercoagulability as further aggravated by surgery and systemic anticancer therapies. The listed sources also identify direct oral anticoagulants as a subject of systematic review and meta-analysis, but do not provide comparative results here. For cancer-associated VTE, guideline recommendations call for discussing anticoagulation duration after six months, while robust tools to assess recurrence and bleeding risks are still needed.
Why Are Cancer Patients More Prone to Blood Clots?
Cancer triggers significant changes in the body's coagulation processes. Biochemical markers consistently show increased activity in both plasma and platelets, indicating a procoagulant state. This includes elevated levels of prothrombin fragments, thrombin-antithrombin complexes, and increased fibrin generation and degradation, reflected in elevated D-dimer levels.
- Tumor interactions: Cancer cells directly interact with the coagulation system, promoting clot formation.
- Inflammation: Cancer-related inflammation activates clotting pathways.
- Immobility: Reduced physical activity during cancer treatment increases the risk of blood clots.
- Treatment effects: Chemotherapy and other treatments can damage blood vessels and further stimulate clotting.
Research on Clotting and Bleeding Together
A 2025 review describes cancer-associated thrombosis, particularly VTE, as the second-highest cause of mortality in patients with cancer, after the cancer itself. It discusses tumor cells as drivers of a prothrombotic environment. A 2026 perspective frames active malignancy as a precarious balance between thrombosis and bleeding shaped by tumor biology, systemic inflammation, treatment toxicity, and progressive frailty. Research also includes an evaluation of the association between anticoagulant-related bleeding and mortality in patients with hematological malignancies treated for cancer-associated VTE, although the supplied source summary does not report its findings.
Heparin Options and a Rare Complication
A randomized study in patients with deep-vein thrombosis reported that both low-molecular-weight heparin and standard subcutaneous heparin reduced thrombus, describing effectiveness for each treatment. A separate source reports heparin-induced thrombocytopenia with thrombosis in about one of every 2,000 patients treated with heparin for five days. Another report describes a patient who developed thrombocytopenia with thrombotic complications while receiving prophylactic low-molecular-weight heparin, without prior unfractionated-heparin injections. These source summaries do not establish a direct comparative safety rate between the heparin regimens.
Striking the Balance: Managing Coagulation in Cancer Care
Managing coagulation in cancer patients requires a delicate balance, mindful of both thrombotic and bleeding risks. Awareness of VTE's high frequency and mortality in cancer underscores the importance of proactive strategies. While low-molecular-weight heparin (LMWH) has been a mainstay for VTE prevention and treatment, recent studies and evolving guidelines suggest a shifting landscape. Direct oral anticoagulants (DOACs) are emerging as valuable options, offering potential benefits in efficacy and convenience.
Why Cancer-Related Clots Matter
Venous thromboembolism in patients with cancer can take the form of deep-vein thrombosis or pulmonary embolism. A 2022 review describes VTE as a common cancer complication associated with high morbidity and mortality. The review considers the mechanisms behind thrombotic complications as well as evidence and future perspectives for their prevention and treatment.
Toward Treatments That Separate Clotting From Hemostasis
A review of cancer-associated thrombosis traces landmark studies that have shaped treatment and discusses factors affecting management and future treatment considerations. A 2026 review identifies a research priority: investigating molecular pathways that could decouple thrombosis from physiological hemostasis. It highlights “dual effect” agents intended to inhibit both tumor progression and thrombogenesis as a direction for future research, rather than an established treatment approach.
Treatment Complexity and Catheter Risks
Managing cancer-associated thrombosis is challenging because of increased bleeding tendency, frailty, and drug interactions. A review notes that low-molecular-weight heparin was the drug of choice for many years. Meanwhile, indwelling catheters used to administer systemic anticancer drugs have supported outpatient cancer care but remain associated with complications including infection, phlebitis, and thrombosis.
Real-World Treatment and Uneven Risk
A single-center retrospective cohort study compared low-molecular-weight heparins with direct oral anticoagulants for treating VTE in patients with cancer, using real-world experience to examine treatment patterns and bleeding. Separately, a large Netherlands case-control study included 3,220 cancer patients aged 18 to 70 and reported an overall venous-thrombosis risk seven times higher. The source summary says the risk was highest in the first few months after diagnosis and was especially elevated among patients with hematological malignancies, lung cancer, or gastrointestinal cancer.